Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy.

Brodie MJ, Chadwick DW, Anhut H, Otte A, Messmer SL, Maton S, Sauermann W, Murray G, Garofalo EA; Gabapentin Study Group 945-212.

Epilepsia. 2002 Sep;43(9):993-1000.

2.

Monotherapy trials with gabapentin for partial epilepsy.

Beydoun A.

Epilepsia. 1999;40 Suppl 6:S13-6; discussion S73-4. Review.

3.

Gabapentin.

Morris GL.

Epilepsia. 1999;40 Suppl 5:S63-70. Review.

4.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

5.

Antiepileptic drugs in development: prospects for the near future.

Leppik IE.

Epilepsia. 1994;35 Suppl 4:S29-40. Review.

PMID:
8174517
6.

Pregabalin monotherapy for epilepsy.

Zhou Q, Zheng J, Yu L, Jia X.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD009429. doi: 10.1002/14651858.CD009429.pub2. Review.

PMID:
23076957
7.

Advances in the pharmacotherapy of epilepsy.

Ramsay RE.

Epilepsia. 1993;34 Suppl 5:S9-16. Review.

PMID:
8339715
8.

Clinical efficacy and safety of gabapentin.

Ramsay RE.

Neurology. 1994 Jun;44(6 Suppl 5):S23-30; discussion S31-2. Review.

PMID:
8022537
9.

Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee; American Epilepsy Society Quality Standards Subcommittee.

Epilepsia. 2004 May;45(5):410-23. Review. Erratum in: Epilepsia. 2004 Nov;45(11):1299.

10.

Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; American Academy of Neurology Therapeutics and Technology Assessment Subcommittee; American Academy of Neurology Quality Standards Subcommittee; American Epilepsy Society Quality Standards Subcommittee; American Epilepsy Society Therapeutics and Technology Assessment Subcommittee.

Epilepsia. 2004 May;45(5):401-9. Review.

11.

Lamotrigine XR conversion to monotherapy: first study using a historical control group.

French JA, Temkin NR, Shneker BF, Hammer AE, Caldwell PT, Messenheimer JA.

Neurotherapeutics. 2012 Jan;9(1):176-84. doi: 10.1007/s13311-011-0088-3. Review.

12.

Overview of the safety of newer antiepileptic drugs.

Shorvon S, Stefan H.

Epilepsia. 1997;38 Suppl 1:S45-51. Review.

13.

[Gabapentin in children and adolescents with epilepsy].

Herranz JL.

Rev Neurol. 2002 Feb 16-28;34(4):384-7. Review. Spanish.

14.

Gabapentin add-on for drug-resistant partial epilepsy.

Marson AG, Kadir ZA, Hutton JL, Chadwick DW.

Cochrane Database Syst Rev. 2000;(3):CD001415. Review. Update in: Cochrane Database Syst Rev. 2013;7:CD001415.

PMID:
10908495
15.

ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.

Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Chadwick D, Guerreiro C, Kalviainen R, Mattson R, Perucca E, Tomson T.

Epilepsia. 2006 Jul;47(7):1094-120. Review.

16.
17.

Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, Theodore WH, Bazil C, Stern J, Schachter SC, Bergen D, Hirtz D, Montouris GD, Nespeca M, Gidal B, Marks WJ Jr, Turk WR, Fischer JH, Bourgeois B, Wilner A, Faught RE Jr, Sachdeo RC, Beydoun A, Glauser TA; Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society.

Neurology. 2004 Apr 27;62(8):1252-60. Review.

PMID:
15111659
18.

Gabapentin for drug-resistant partial epilepsy.

Marson AG, Kadir ZA, Hutton JL, Chadwick DW.

Cochrane Database Syst Rev. 2000;(2):CD001415. Review. Update in: Cochrane Database Syst Rev. 2000;(3):CD001415.

PMID:
10796785
19.

New antiepileptic drugs for children: felbamate, gabapentin, lamotrigine, and vigabatrin.

Devinsky O, Vazquez B, Luciano D.

J Child Neurol. 1994 Oct;9 Suppl 1:S33-45. Review.

PMID:
7822751
20.

Gabapentin and lamotrigine: novel antiepileptic drugs.

Btaiche IF, Woster PS.

Am J Health Syst Pharm. 1995 Jan 1;52(1):61-9. Review.

PMID:
12879525
Items per page

Supplemental Content

Write to the Help Desk